Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Neuropathol Appl Neurobiol ; 39(7): 750-61, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23452232

RESUMEN

AIMS: Sporadic inclusion-body myositis (s-IBM) is an age-associated degenerative muscle disease. Characteristic features are muscle-fibre vacuolization and intramuscle-fibre accumulations of multiprotein aggregates, which may result from the demonstrated impairments of the 26S proteasome and autophagy. Chaperone-mediated autophagy (CMA) is a selective form of lysosomal degradation targeting proteins carrying the KFERQ motif. Lysosome-associated membrane protein type 2A (LAMP2A) and the heat-shock cognate protein 70 (Hsc70) constitute specific CMA components. Neither CMA components nor CMA activity has been studied in normal or disease human muscle, to our knowledge. METHODS: We studied CMA components by immunocytochemistry, immunoblots, real-time PCR and immunoprecipitation in: (a) 16 s-IBM, nine aged-matched normal and nine disease control muscle biopsies; and (b) cultured human muscle fibres (CHMFs) with experimentally inhibited activities of either the 26S proteasome or autophagy. RESULTS: Compared with age-matched controls, in s-IBM muscle, LAMP2A and Hsc70 were on a given transverse section accumulated as aggregates in approximately 5% of muscle fibres, where they (a) colocalized with each other and α-synuclein (α-syn), a CMA-targeted protein; and (b) were bound to each other and to α-syn by immunoprecipitation. By immunoblots, LAMP2A was increased sevenfold P < 0.001 and Hsc70 2.6-fold P < 0.05. LAMP2A mRNA was increased 4.4-fold P < 0.001 and Hsc70 mRNA 1.9-fold P < 0.05. In CHMFs inhibition of either the 26S proteasome or autophagy induced CMA, evidenced by a significant increase of both LAMP2A and Hsc70. CONCLUSIONS: Our study demonstrates, for the first time, up-regulation of CMA components in s-IBM muscle, and it provides further evidence that altered protein degradation is likely an important pathogenic aspect in s-IBM.


Asunto(s)
Autofagia/fisiología , Proteínas de la Membrana/metabolismo , Chaperonas Moleculares/metabolismo , Fibras Musculares Esqueléticas/metabolismo , Miositis por Cuerpos de Inclusión/metabolismo , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Lisosomas/metabolismo , Masculino , Persona de Mediana Edad , Fibras Musculares Esqueléticas/patología , Miositis por Cuerpos de Inclusión/patología , Complejo de la Endopetidasa Proteasomal/metabolismo , ARN Mensajero/metabolismo , Regulación hacia Arriba/fisiología , alfa-Sinucleína/metabolismo
2.
Acta Myol ; 29(1): 1-20, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22029103

RESUMEN

A second genetic revolution is approaching thanks to next-generation DNA sequencing technologies. In the next few years, the 1,000$-genome sequencing promises to reveal every individual variation of DNA. There is, however, a major problem: the identification of thousands of nucleotide changes per individual with uncertain pathological meaning. This is also an ethical issue. In the middle, there is today the possibility to address the sequencing analysis of genetically heterogeneous disorders to selected groups of genes with defined mutation types. This will be cost-effective and safer. We assembled an easy-to manage overview of most Mendelian genes involved in myopathies, cardiomyopathies, and neuromyopathies. This was entirely put together using a number of open access web resources that are listed below. During this effort we realized that there are unexpected countless sources of data, but the confusion is huge. In some cases, we got lost in the validation of disease genes and in the difficulty to discriminate between polymorphisms and disease-causing alleles. In the table are the annotated genes, their associated disorders, genomic, mRNA and coding sizes. We also counted the number of pathological alleles so far reported and the percentage of single nucleotide mutations.


Asunto(s)
Cardiomiopatías/genética , Enfermedades Musculares/genética , Enfermedades Neuromusculares/genética , Polineuropatías/genética , Análisis Mutacional de ADN , Variación Genética , Genoma Humano , Humanos , Polimorfismo de Nucleótido Simple , Análisis de Secuencia de ADN
3.
Acta Neuropathol Commun ; 7(1): 82, 2019 05 21.
Artículo en Inglés | MEDLINE | ID: mdl-31113487

RESUMEN

Microglia affect Alzheimer's disease (AD) pathogenesis in opposing manners, by protecting against amyloid accumulation in early phases of the disease and promoting neuropathology in advanced stages. Recent research has identified specific microglial interactions with amyloid plaques that exert important protective functions including attenuation of early pathology. It is unknown how these protective microglial interactions with plaques are affected by apolipoprotein E (APOE) genotype and sex, two well-established AD risk factors that modulate microglial function. We investigated this question using quantitative confocal microscopy to compare microglial interactions with amyloid plaques in male and female EFAD mice across APOE3 and APOE4 genotypes at 6 months of age. We observed that microglial coverage of plaques is highest in male APOE3 mice with significant reductions in coverage observed with both APOE4 genotype and female sex. Plaque compaction, a beneficial consequence of microglial interactions with plaques, showed a similar pattern in which APOE4 genotype and female sex were associated with significantly lower values. Within the plaque environment, microglial expression of triggering receptor expressed on myeloid cells 2 (TREM2), a known regulator of microglial plaque coverage, was highest in male APOE3 mice and reduced by APOE4 genotype and female sex. These differences in plaque interactions were unrelated to the number of microglial processes in the plaque environment across groups. Interestingly, the pattern of amyloid burden across groups was opposite to that of microglial plaque coverage, with APOE4 genotype and female sex showing the highest amyloid levels. These findings suggest a possible mechanism by which microglia may contribute to the increased AD risk associated with APOE4 genotype and female sex.


Asunto(s)
Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/patología , Apolipoproteína E3/genética , Apolipoproteína E4/genética , Encéfalo/patología , Microglía/patología , Placa Amiloide/patología , Animales , Femenino , Genotipo , Masculino , Glicoproteínas de Membrana/metabolismo , Ratones Transgénicos , Receptores Inmunológicos/metabolismo , Caracteres Sexuales
4.
Acta Myol ; 27: 90-7, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19472918

RESUMEN

The term limb-girdle muscular dystrophies (LGMD) identify about two dozens of distinct genetic disorders. Additional genes must play a role, since there are LGMD families excluded from any known locus. The aim of our work is to test a number of candidate genes in unclassified LGMD patient and control DNA samples. We selected the following 11 candidate genes: myozenin 1, 2 and 3, gamma-filamin, kinectin-1, enolase-3 beta, ZASP, TRIM 11 and TRIM 17, OZZ and zeta-sarcoglycan. These candidates were chosen for a combination of different reasons: chromosomal position, sequence homology, interaction properties or muscular dystrophy phenotypes in animal models. The exon and flanking intron sequences were subjected to molecular testing by comparative mutation scanning by HT-DHPLC of LGMD patients versus control. We identified a large number of variations in any of the genes in both patients and controls. Correlations with disease or possible modifying effects on the LGMD phenotype remain to be investigated.


Asunto(s)
Proteínas Portadoras/genética , Proteínas Contráctiles/genética , Perfilación de la Expresión Génica , Pruebas Genéticas/métodos , Proteínas de la Membrana/genética , Proteínas de Microfilamentos/genética , Proteínas Musculares/genética , Distrofia Muscular de Cinturas/genética , Mutación/genética , Proteínas Adaptadoras Transductoras de Señales/genética , Estudios de Casos y Controles , Estudios de Cohortes , Filaminas , Humanos , Proteínas con Dominio LIM , Fosfopiruvato Hidratasa/genética , Sarcoglicanos/genética , Proteínas de Motivos Tripartitos , Complejos de Ubiquitina-Proteína Ligasa , Ubiquitina-Proteína Ligasas/genética
5.
Transl Psychiatry ; 7(1): e1022, 2017 01 31.
Artículo en Inglés | MEDLINE | ID: mdl-28140404

RESUMEN

Exposure to particulate matter (PM) in the ambient air and its interactions with APOE alleles may contribute to the acceleration of brain aging and the pathogenesis of Alzheimer's disease (AD). Neurodegenerative effects of particulate air pollutants were examined in a US-wide cohort of older women from the Women's Health Initiative Memory Study (WHIMS) and in experimental mouse models. Residing in places with fine PM exceeding EPA standards increased the risks for global cognitive decline and all-cause dementia respectively by 81 and 92%, with stronger adverse effects in APOE ɛ4/4 carriers. Female EFAD transgenic mice (5xFAD+/-/human APOE ɛ3 or ɛ4+/+) with 225 h exposure to urban nanosized PM (nPM) over 15 weeks showed increased cerebral ß-amyloid by thioflavin S for fibrillary amyloid and by immunocytochemistry for Aß deposits, both exacerbated by APOE ɛ4. Moreover, nPM exposure increased Aß oligomers, caused selective atrophy of hippocampal CA1 neurites, and decreased the glutamate GluR1 subunit. Wildtype C57BL/6 female mice also showed nPM-induced CA1 atrophy and GluR1 decrease. In vitro nPM exposure of neuroblastoma cells (N2a-APP/swe) increased the pro-amyloidogenic processing of the amyloid precursor protein (APP). We suggest that airborne PM exposure promotes pathological brain aging in older women, with potentially a greater impact in ɛ4 carriers. The underlying mechanisms may involve increased cerebral Aß production and selective changes in hippocampal CA1 neurons and glutamate receptor subunits.


Asunto(s)
Disfunción Cognitiva/epidemiología , Demencia/epidemiología , Exposición a Riesgos Ambientales/estadística & datos numéricos , Interacción Gen-Ambiente , Material Particulado , Anciano , Enfermedad de Alzheimer/epidemiología , Enfermedad de Alzheimer/genética , Péptidos beta-Amiloides/efectos de los fármacos , Péptidos beta-Amiloides/metabolismo , Animales , Apolipoproteína E4/genética , Atrofia , Región CA1 Hipocampal/efectos de los fármacos , Región CA1 Hipocampal/patología , Línea Celular Tumoral , Cerebro/efectos de los fármacos , Cerebro/metabolismo , Disfunción Cognitiva/genética , Demencia/genética , Femenino , Humanos , Técnicas In Vitro , Ratones , Ratones Transgénicos , Neuritas/efectos de los fármacos , Neuritas/patología , Receptores AMPA/efectos de los fármacos , Receptores AMPA/metabolismo
6.
Artículo en Inglés | MEDLINE | ID: mdl-28042517

RESUMEN

Cerebral microbleeds (MB) and small vessel disease (SVD) with congophilic arterial angiopathy (CAA) are increasingly recognized as a variable factor in AD cognitive impairments. This commentary on our recent report on sex-ApoE interactions in MBs published this February, briefly explores three aspects of MBs that could not be fully discussed therein: I, A possible gap between the prevalence of MBs as detected by MRI and post mortem analysis; II, The role of hemoglobin-degradation products in amyloid-attributed neurodegenerative changes; and III, Possible assessment of MB by cerebrospinal fluid (CSF) assays for iron-related markers to better screen patient subgroups for AD interventions.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA